| In vivo knockdown of pathogenic proteins via specific and nongenetic inhibitor of apoptosis protein (IAP)-dependent protein erasers (SNIPERs) N Ohoka, K Okuhira, M Ito, K Nagai, N Shibata, T Hattori, O Ujikawa, ... Journal of Biological Chemistry 292 (11), 4556-4570, 2017 | 273 | 2017 |
| Discovery of a Thieno[2,3-d]pyrimidine-2,4-dione Bearing a p-Methoxyureidophenyl Moiety at the 6-Position: A Highly Potent and Orally Bioavailable Non … S Sasaki, N Cho, Y Nara, M Harada, S Endo, N Suzuki, S Furuya, ... Journal of medicinal chemistry 46 (1), 113-124, 2003 | 229 | 2003 |
| Discovery of a novel, potent, and orally active nonpeptide antagonist of the human luteinizing hormone-releasing hormone (LHRH) receptor N Cho, M Harada, T Imaeda, T Imada, H Matsumoto, Y Hayase, S Sasaki, ... Journal of medicinal chemistry 41 (22), 4190-4195, 1998 | 177 | 1998 |
| Development of protein degradation inducers of androgen receptor by conjugation of androgen receptor ligands and inhibitor of apoptosis protein ligands N Shibata, K Nagai, Y Morita, O Ujikawa, N Ohoka, T Hattori, R Koyama, ... Journal of medicinal chemistry 61 (2), 543-575, 2018 | 165 | 2018 |
| Discovery of potent Mcl-1/Bcl-xL dual inhibitors by using a hybridization strategy based on structural analysis of target proteins Y Tanaka, K Aikawa, G Nishida, M Homma, S Sogabe, S Igaki, Y Hayano, ... Journal of medicinal chemistry 56 (23), 9635-9645, 2013 | 132 | 2013 |
| K-Ras (G12D)-selective inhibitory peptides generated by random peptide T7 phage display technology K Sakamoto, Y Kamada, T Sameshima, M Yaguchi, A Niida, S Sasaki, ... Biochemical and biophysical research communications 484 (3), 605-611, 2017 | 126 | 2017 |
| Cancer cell death induced by novel small molecules degrading the TACC3 protein via the ubiquitin–proteasome pathway N Ohoka, K Nagai, T Hattori, K Okuhira, N Shibata, N Cho, M Naito Cell death & disease 5 (11), e1513-e1513, 2014 | 124 | 2014 |
| Derivatization of inhibitor of apoptosis protein (IAP) ligands yields improved inducers of estrogen receptor α degradation N Ohoka, Y Morita, K Nagai, K Shimokawa, O Ujikawa, I Fujimori, M Ito, ... Journal of Biological Chemistry 293 (18), 6776-6790, 2018 | 120 | 2018 |
| Peroxisome proliferator-activated receptor γ agonists as insulin sensitizers: from the discovery to recent progress N Cho, Y Momose Current topics in medicinal chemistry 8 (17), 1483-1507, 2008 | 119 | 2008 |
| Development of protein degradation inducers of oncogenic BCR‐ABL protein by conjugation of ABL kinase inhibitors and IAP ligands N Shibata, N Miyamoto, K Nagai, K Shimokawa, T Sameshima, N Ohoka, ... Cancer science 108 (8), 1657-1666, 2017 | 115 | 2017 |
| Targeting the allosteric site of oncoprotein BCR-ABL as an alternative strategy for effective target protein degradation K Shimokawa, N Shibata, T Sameshima, N Miyamoto, O Ujikawa, H Nara, ... ACS medicinal chemistry letters 8 (10), 1042-1047, 2017 | 101 | 2017 |
| SNIPER (TACC3) induces cytoplasmic vacuolization and sensitizes cancer cells to Bortezomib N Ohoka, K Nagai, N Shibata, T Hattori, H Nara, N Cho, M Naito Cancer Science 108 (5), 1032-1041, 2017 | 69 | 2017 |
| Molecular mechanism and potential target indication of TAK-931, a novel CDC7-selective inhibitor K Iwai, T Nambu, R Dairiki, M Ohori, J Yu, K Burke, M Gotou, Y Yamamoto, ... Science advances 5 (5), eaav3660, 2019 | 65 | 2019 |
| Pharmacological difference between degrader and inhibitor against oncogenic BCR-ABL kinase N Shibata, K Shimokawa, K Nagai, N Ohoka, T Hattori, N Miyamoto, ... Scientific reports 8 (1), 13549, 2018 | 59 | 2018 |
| Prophylactic/Therapeutic Agent for Diabetes N Cho, S Kasai, T Yamashita US Patent App. 11/887,358, 2009 | 54 | 2009 |
| Suppression of a pituitary-ovarian axis by chronic oral administration of a novel nonpeptide gonadotropin-releasing hormone antagonist, TAK-013, in cynomolgus monkeys T Hara, H Araki, M Kusaka, M Harada, N Cho, N Suzuki, S Furuya, ... The Journal of Clinical Endocrinology & Metabolism 88 (4), 1697-1704, 2003 | 52 | 2003 |
| Different degradation mechanisms of inhibitor of apoptosis proteins (IAPs) by the specific and nongenetic IAP-dependent protein eraser (SNIPER) N Ohoka, O Ujikawa, K Shimokawa, T Sameshima, N Shibata, T Hattori, ... Chemical and Pharmaceutical Bulletin 67 (3), 203-209, 2019 | 49 | 2019 |
| Thienopyrimidine compounds and use thereof N Cho, T Imada, T Hitaka, K Miwa, M Kusaka, N Suzuki US Patent 7,300,935, 2007 | 40 | 2007 |
| A new class of potent nonpeptide luteinizing hormone-releasing hormone (LHRH) antagonists: design and synthesis of 2-phenylimidazo [1, 2-a] pyrimidin-5-ones S Sasaki, T Imaeda, Y Hayase, Y Shimizu, S Kasai, N Cho, M Harada, ... Bioorganic & medicinal chemistry letters 12 (16), 2073-2077, 2002 | 28 | 2002 |
| Thienopyrimidine compounds and use thereof N Cho, T Imada, T Hitaka, K Miwa, M Kusaka, N Suzuki US Patent 9,346,822, 2016 | 27 | 2016 |
